552 related articles for article (PubMed ID: 30362019)
21. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
22. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
23. Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
Stokke JL; Bhojwani D
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441852
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
[TBL] [Abstract][Full Text] [Related]
25. Inotuzumab Ozogamicin: First Pediatric Approval.
Dhillon S
Paediatr Drugs; 2024 May; ():. PubMed ID: 38780741
[TBL] [Abstract][Full Text] [Related]
26. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
Rossi C; Chrétien ML; Casasnovas RO
Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
[TBL] [Abstract][Full Text] [Related]
28. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
30. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
Prakash R; Subbiah V; Iyer SP
Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
[TBL] [Abstract][Full Text] [Related]
31. Antibody-Drug Conjugates for Cancer Treatment.
Lambert JM; Berkenblit A
Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
[TBL] [Abstract][Full Text] [Related]
32. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
33. Antibody-Drug Conjugates in Myeloid Leukemias.
Senapati J; Daver NG; Pemmaraju N
Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
[TBL] [Abstract][Full Text] [Related]
34. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
36. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
37. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia.
Yilmaz M; Richard S; Jabbour E
Ther Adv Hematol; 2015 Oct; 6(5):253-61. PubMed ID: 26425338
[TBL] [Abstract][Full Text] [Related]
38. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
39. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
Uy N; Nadeau M; Stahl M; Zeidan AM
J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]